Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 189-197

  Chinol, M ^a   Casalini, P ^b   Maggiolo, M ^a   Canevari, S ^b   Omodeo, E S ^a   Caliceti, P ^c   Veronese, F M ^c   Cremonesi, M ^a   Chiolerio, F ^d   Nardone, E ^e   Siccardi, A G ^e   Paganelli, G ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d Società Prodotti Antibiotici   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Immunogenicity; Modified avidin; Pharmacokinetics; Polyethylene glycol; Recombinant avidin; Three step pretargeting

Indexed keywords

AVIDIN; BIOTIN; CARBOHYDRATE; MACROGOL; STREPTAVIDIN; SUCCINIC ANHYDRIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; CANCER THERAPY; CONJUGATION; DRUG TARGETING; FEMALE; IMMUNOGENICITY; KIDNEY; LIVER; MOUSE; NONHUMAN; PHARMACOKINETICS; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN MODIFICATION;

EID: 7144235821     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.463     Document Type: Article

References (46)

1. Alvarez-Diez TM, Polihronis J and Reilly RM (1996) Pretargeted tumour imaging with streptavidin immunoconjugates of monoclonal antibody CC49 and in-DTPA-biocytin. Nucl Med Biol 23: 459-466
2. Axworthy DB, Fritzberg AR, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su FM, Beaumier PL and Reno JM (1995) Preclinical evaluation of an anti-tumor monoclonal antibody/streptavidin conjugate for pretargeted Y radioimmunotherapy in a mouse xenograft model. J Immunother 16: 138
3. Beaumier PL, Axworthy DB, Fritzberg AR, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, Su F-M and Reno JM (1995) The pharmacology of pretargeting components: optimizing therapeutic targeting. Q J Nucl Med 39: 20
4. Bidligmeyer BA, Cohen SA and Tarvin TL (1984) Rapid analysis of aminoacids using pre-column derivatization. J Chromatogr 336: 93-104
5. Border WA, Ward HJ, Kamil ES and Cohen AH (1982) Induction of membranous nephtopathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest 69: 451-461
6. Bruch RC and White HB (1982) Compositional and structural heterogeneity of avidin glycopeptides. Biolchemistry 21: 5334-5341
7. Caliceti P, Morpurgo M, Schiavon O, Monfardini C and Veronese FM (1994) Preservation of thrombolytic activity of urokinase modified with monomethoxypoly (ethylene glycol). J Bioactive and Campatible Polymers 9: 252-266
8. Chaiet L and Wolf FJ (1964) The properties of streptavidin: a biotin-binding protein produced by Streptomycetes. Arch Biochem Biophys 106: 1-5
9. Delange RJ (1970) Egg white avidin I. Amino acid composition; sequence of the amino- and carboxyl-terminal cyanogen bromide peptides. J Biol Chem 245: 907-916
10. Delgado C, Francis GE and Fisher D (1992) Uses and properties of PEG-linked protiens. In Critical Reviews in Therapeutic Drug Carrier Systems. Bruck SD fed.), pp 249-304. CRC Press: Boca Raton, FL.
11. Delgado C, Pedley RB, Herraez A, Boden R, Boden JA, Keep PA, Chester KA, Fisher D, Begent RHJ and Francis GE (1996) Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification. Br J Cancer 73: 175-182
12. Fazio F and Paganelli G (1993) Antibody-guided scintigraphy: targeting of the 'magic bullet' Eur J Nucl Med 20: 1138-1140
13. Gitlin G, Bayer EA and Wilchek M (1990) Studies on the biotin-binding sites of avidin and streptavidin. Biochem J 269: 527-530
14. Goodwin DA (1995) Tumor pretargeting: almost the bottom line. J Nucl Med 36: 876-879
15. Gornall AG, Bardawill CJ and David MM (1949) Determination of serum protein by means of biuret reaction. J Biol Chem 177: 751-766
16. Grana C, Chinol M, Mugnani P, Corti A, Sidoli A, Siccardi AG and Paganelli G (1996) In vivo tumor targeting based on the avidin-biotin system. Tumor Targeting 2: 230-239
17. Green NM (1970) Spectrophotometric determination of avidin and biotin. Methods Enzymol 18A: 418-424
18. Geen NM (1975) Avidin. In Advances in Protein Chemistry. Anfinsen CB. Edsall JT and Richards FM (eds), vol. 29, pp. 85-133. Academic Press, New York
19. Hnatowich DJ, Virzi F and Rusckowski M (1987) Investigations of and biotin for imaging applications. J Nucl Med 28: 1294-1302
20. Hunter WM and Greenwood FC (1962) Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 194: 495-496
21. Kamisaki Y, Wada H, Yagura T, Matsushima A and Inada Y (1981) Reduction in immunogenicity and clearance rate of Escherichiya coli 1 -asparaginase by modification with mono-methoxythylene glycol. J Pharmacol Exp Ther 216: 410-414
22. +H]biotin bound to different avidin analogues. J Drug Targeting 3: 159-165
23. Kartre K (1993) The conjugation of proteins with polyethylene glycol and other polymers. Adv Drug Deliv Rev 10: 91-114
24. Kaseda N, Uehara Y, Yamamoto Y and Tanaka K (1985) Induction of in situ immune complexes in rat glomeruli using avidin. a native cation macromolecule. Br J Exp Pathol 66: 729-736
25. Kobayashi H, Sakahara H, Hosono M, Yao ZS and Toyama S (1994) Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a 'chase' without decreased accumulation in the target tumor. J Nucl Med 35: 1677-1684
26. Lacmmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
27. Magnani P. Paganelli G, Modorati G, Zito F, Songini C, Sudati F, Koch P, Maecke HR, Brancato R, Siccardi AG and Fazio F (1996) Quantitative comparison of direct antibody labeling and tumor pretargeting in uveal melanoma. J Nucl Med 37: 967-971
28. Marshall D, Pedley RB, Boden JA, Boden R, Melton RG and Begent RHJ (1996) Polyethlene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody. Br J Cancer 73: 565-572
29. Nucci ML, Shorr R and Abuchowski A (1991) The therapeutic nature of poly(ethylene glycol) modified proteins. Adv Drug Deliv Rev 6: 133-155
30. Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Seassellati GA and Epenetos AA (1990) Intraperitoneal radioloalization of tumors pre-targeted by biotinylated monoclonal antibodies. Int J Cancer 45: 1184-1189
31. Paganelli G, Stella M, Zito F, Magnani P, De Nardi P, Mangili F, Baratti D, Veglia F, Di Carlo V, Siccardi AG and Fazio F (1994) Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin, J Nucl Med 35: 1970-1975
32. Paganelli G, Magnani P, Siccardi AG and Fazio F (1995) Clinical application of the avidin-biotin system for tumor targeting. In Cancer Therapy with Radiolabeled Antibodies. Goldenberg DM (ed.), pp. 239-254, CRC Press: Boca Raton, FL
33. Paganelli G, Grana C, Chinol M, De Cicco C, Cremonesi M, Tarditi L, Franceschini R. Zoboli S, De Braud F and Siccardi AG (1996) Therapy trial in malignant glioma patients with Y-90-biotin in a 3-step pretargeting approach. J Nucl Med 37 (Suppl.): 169P-170P
34. Paganelli G, Grana C, Chinol M, Cremonesi M, De Cicco C, De Braud F, Maggiolo M and Siccardi AG (1997a) Antibody guided three-step radiotherapy with Y-biotin in glioma patients. Eur J Nucl Med 24: 908
35. Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S, Siccardi AG (1997b) The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med 24: 350-351
36. Rosebrough SF (1993) Pharmacokinetics and biodistribution of radiolabeled avidin. streptavidin and biotin. Nucl Med Biol 20: 663-668
37. Rosebrough SF and Hartley DF (1996) Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J Nucl Med 37: 1380-1384
38. Samuel A, Paganelli G, Chiesa R, Sudati F, Calvitto M, Melissano G, Grossi A and Fazio F (1996) Detection of prosthetic vascular graft infection using avidin/indium-111-biotin scintigraphy. J Nucl Med 37: 55-61
39. Sartore L, Calieeti P, Schiavon O and Veronese FM (1991) Enzime modification by MPEG with an amino acid or peptide as space arms. Appl Biochem Biotechnol 27: 45-54
40. Sehechter B, Silberman R, Arnon R and Wilchek M (1990) Tissue distribution of avidin and streptavidin injected to mice, Effect of avidin carbohydrate. streptavidin truncation and exogenous biotin. Eur J Biochem 189: 327-331
41. Shin S-U, Wu D, Ramanathan R, Pardridge WM and Morrison SL (1997) Functional and pharmacokinetic properties of antibody avidin fusion proteins. J Immunol 158: 4797-4804
42. Sims GEC and Snape TJ (1980) A method for estimation of poly(ethylene glycol) in plasma protein fractions. Anal Biochem 107: 60-63
43. Sung C, Van Osdol WW, Saga T, Neumann RD, Dedrick RL and Weinstein JN (1994) Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics. Cancer Res 54: 2166-2175
44. Veronese FM, Monfardini C, Caliceti P, Schiavon O, Scrawen MD and Beer D (1996) Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol). J Control Release 40: 199-209
45. Wilchek M and Bayer EA (1988) The avidin-biotin complex in bioanalytical applications. Anal Biochem 171: 1-32
46. Wilchek M and Bayer EA (1989) Avidin-biotin technology ten years on: has it lived up to its expectations? Trends Biol Sci 14: 408-413